ASTRAZENECA PLC ANNOUNCES TAGRISSO GRANTED BREAKTHROUGH THERAPY DESIGNATION BY US FDA
Designation based on positive Phase III FLAURA trial resultsSixth Breakthrough Therapy Designation for an AstraZeneca New Oncology medicine9 October 2017 07:00 BST TAGRISSO GRANTED BREAKTHROUGH THERAPY DESIGNATION BY US FDA FOR THE 1ST-LINE TREATMENT OF PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-